March 11, 2020 / 7:54 PM / 23 days ago

BRIEF-New Clinical Study Data For Gilead’S Investigational HIV-1 Capsid Inhibitor GS-6207 Presented At CROI 2020

March 11 (Reuters) - Gilead Sciences Inc:

* NEW CLINICAL STUDY DATA FOR GILEAD’S INVESTIGATIONAL HIV-1 CAPSID INHIBITOR GS-6207 PRESENTED AT CROI 2020

* GILEAD SCIENCES INC - PHASE 1B STUDY DEMONSTRATES POTENTIAL OF GS-6207 TO RAPIDLY REDUCE VIRAL LOAD AFTER A SINGLE SUBCUTANEOUS INJECTION Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below